Customize
Quick Links
Specialties

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.

Resources

Pulse Recaps for Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid Malignancies

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie Inc., Acerta Pharma – A member of the AstraZeneca Group, Bristol-Myers Squibb, and Celgene..

Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid Malignancies

Release Date: January 30, 2017
Expiration Date: January 30, 2018
Media: Internet - based

 

Activity Overview

Community Practice Connections: 1st Annual European Congress on Hematology™: Focus on Lymphoid Malignancies consists of a series of interactive clinical vignettes, short video interviews with leading experts in hematologic malignancies, and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie Inc., Acerta Pharma – A member of the AstraZeneca Group, Bristol-Myers Squibb, and Celgene..

CME/CE Activity Table of Contents

  • Module 1: Chronic Lymphocytic Leukemia
  • Module 2: Multiple Myeloma
  • Module 3: Lymphomas

Requirements for Successful Completion

In order to receive a CME/CE certificate, participants must view any number of the modules, complete the posttest with a passing score of 70% or higher, complete the evaluation, and request credit. Participants may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This educational activity is directed toward medical oncologists and other healthcare professionals (eg, physicians, physicians-in-training, oncology nurses, pharmacists, physicians' assistants) involved in the treatment and management of patients with hematologic malignancies.

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

  • Describe current and evolving genomic and molecular biomarkers that can be used to stratify risk and inform clinical decision making in the management of hematologic malignancies
  • Assess landmark clinical trial results in the context of how they impact evolving clinical practice paradigms and can be applied to personalize care and optimize outcomes
  • Delineate effective strategies to proactively mitigate and manage predictable side effects related to the management of hematologic malignancies so as to maximize treatment outcomes
  • Discuss effective strategies to assess and address nonadherence to oral oncolytic therapies in the treatment and management of hematological malignancies
  • Evaluate recent clinical trial findings concerning novel compounds or strategies to manage hematologic malignancies
  • Consider the therapeutic implications of emerging data on evolving treatment paradigms for patients with hematologic tumors 

Faculty, Staff, and Planners' Disclosures

Faculty

Philippe Moreau, MD
Head, Hematology Department
University Hospital of Nantes
Nantes, France
Disclosure: Speaker’s Bureau: Takeda, Amgen, Janssen, Celgene


 

Gilles A. Salles, MD, PhD
Department Head
Université Claude Bernard Lyon- 1
Hospices Civils de Lyon
Lyon, France
Disclosure: Grant/Research Support: Roche; Consultant: Amgen, Celgene, Gilead, Janssen, Novartis, Roche

 

Anas Younes, MD
Chief, Lymphoma Service
Division of Hematologic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosure: Grant/Research Support: Novartis, JNJ, Curis, Roche, Bristol-Myers Squibb; Other: Bayer, Bristol-Myers Squibb, Celgene, Incyte, Janssen, Sanofi, Seattle Genetics, Takeda Millennium, Genentech, Merck


Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of Physicians’ Education Resource®, LLC (PER®), to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.

Staff and Planners’ Disclosures

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.

CME Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
info@gotoper.com

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise






Become a Member

Forgot Password?
Filter By